Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MARGENZA vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Margetuximab is an Fc-engineered monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 (HER2). It binds to HER2 on tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) via enhanced affinity for activating Fcγ receptors (FcγRIIIa) and reduced affinity for inhibitory FcγRIIb, thereby augmenting immune effector cell activation.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
FDA-approved: In combination with chemotherapy (capecitabine or gemcitabine plus cisplatin) for the treatment of adults with metastatic or locally advanced unresectable HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received two or more prior anti-HER2 regimens.,Off-label: Not specified in FDA labeling; potential off-label uses may include other HER2-positive malignancies, but none are established.
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
15 mg/kg intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Terminal half-life approximately 17-23 days (mean ~20 days) following intravenous administration, supporting a 3-week dosing interval for sustained receptor occupancy.
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
Margetuximab is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic enzymes or pathways are involved.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Primarily cleared via proteolytic degradation; renal excretion of intact drug is negligible (<1%). No significant biliary or fecal elimination reported.
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
~99% bound to plasma proteins, primarily to albumin and immunoglobulin G (as a monoclonal antibody).
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
Volume of distribution approximately 3.0-4.0 L (0.04-0.06 L/kg). Low Vd indicates limited extravascular distribution, consistent with large antibody molecule primarily confined to plasma and interstitial space.
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
Bioavailability is 100% by intravenous route as it is administered as an IV infusion; not available for oral or other routes.
Intravenous administration yields 100% bioavailability.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
No dose adjustment recommended for mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN, or total bilirubin >1-1.5× ULN with any AST). Not studied in moderate (total bilirubin >1.5-3× ULN with any AST) or severe (total bilirubin >3× ULN with any AST) hepatic impairment.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Safety and effectiveness in pediatric patients have not been established.
Safety and effectiveness in pediatric patients have not been established.
No specific dose adjustment recommended. Of the 292 patients treated with MARGENZA in the SOPHIA trial, 45% were aged 65 years or older, 11% were 75 or older. No overall differences in efficacy or safety observed between elderly and younger patients.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
No black box warning exists for MARGENZA.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Cardiotoxicity: Left ventricular ejection fraction (LVEF) decline; assess LVEF prior to and during treatment. Discontinue for symptomatic heart failure or persistent decline.,Infusion-related reactions: Monitor during infusion; reduce rate or discontinue for severe reactions.,Embryo-fetal toxicity: Can cause fetal harm; advise females of reproductive potential of the risk and use effective contraception.,Pulmonary toxicity: Interstitial lung disease and pneumonitis; monitor for signs/symptoms and permanently discontinue if confirmed.,Neutropenia and febrile neutropenia: May occur; monitor blood counts.,Hypokalemia and hypomagnesemia: Monitor electrolytes and replace as needed.
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
None known.
None known.
No specific food interactions are known. No dietary restrictions required during treatment.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
MARGENZA (margetuximab-cmkb) is an Ig G1 monoclonal antibody. Based on its mechanism of action (HER2/neu receptor blockade) and findings from animal studies with other HER2-targeted agents, it is expected to cause fetal harm or death when administered to a pregnant woman. Human Ig G molecules cross the placenta, with increasing transfer as pregnancy progresses, reaching peak levels during the third trimester. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may have lower risk, but second and third trimester exposure is associated with oligohydramnios, fetal renal dysfunction, and fetal loss.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
There are no data on the presence of margetuximab in human milk, its effects on the breastfed infant, or its effects on milk production. Maternal Ig G is present in human milk, but the amount of margetuximab transferred is expected to be low due to its large molecular size. However, because of the potential for serious adverse reactions in nursing infants, women should discontinue breastfeeding during treatment and for at least 4 months after the last dose. M/P ratio is not available.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
No dosage adjustment is recommended for MARGENZA based on pregnancy-induced pharmacokinetic changes; however, the drug should be avoided during pregnancy due to fetal harm. No specific pharmacokinetic studies have been conducted in pregnant women to warrant dose adjustments.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
MARGENZA (margetuximab-cmkb) is an anti-HER2 monoclonal antibody indicated in combination with chemotherapy for metastatic HER2-positive breast cancer after two or more prior anti-HER2 regimens. Premedicate with acetaminophen, diphenhydramine, and corticosteroids to mitigate infusion-related reactions. Monitor for left ventricular ejection fraction (LVEF) decline; assess cardiac function at baseline and every 3 months during treatment. Use with caution in patients with prior anthracycline exposure or pre-existing cardiac dysfunction.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
MARGENZA is given as an intravenous infusion every 3 weeks; each infusion takes about 90 minutes initially, then 30 minutes if well tolerated.,You may experience infusion-related reactions such as fever, chills, or nausea; you will receive premedication to reduce these.,This drug can cause heart problems; your doctor will monitor your heart function with echocardiograms regularly.,MARGENZA can cause fetal harm if used during pregnancy; use effective contraception during treatment and for 4 months after the last dose.,Do not breastfeed during treatment and for 4 months after the last dose.,Common side effects include fatigue, nausea, diarrhea, and anemia.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MARGENZA vs COLUMVI, answered by our medical review team.
MARGENZA is a Antineoplastic Agent that works by Margetuximab is an Fc-engineered monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 (HER2). It binds to HER2 on tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) via enhanced affinity for activating Fcγ receptors (FcγRIIIa) and reduced affinity for inhibitory FcγRIIb, thereby augmenting immune effector cell activation.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MARGENZA and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MARGENZA is: 15 mg/kg intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MARGENZA and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MARGENZA is classified as Category C. MARGENZA (margetuximab-cmkb) is an IgG1 monoclonal antibody. Based on its mechanism of action (HER2/neu receptor blockade) and findings from animal studies with other HER2-targeted. COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.